Literature DB >> 6106785

Skeletal uptake of diphosphonate. Method for prediction of post-menopausal osteoporosis.

I Fogelman, R G Bessent, H N Cohen, D M Hart, R Lindsay.   

Abstract

24-h whole-body retention (WBR) of diphosphonate (a sensitive indicator of skeletal metabolism) was measured in 37 oophorectomised women. 14 women had been prescribed oestrogen supplements and 3 of these had defaulted from therapy. For the study group there was a significant correlation between WBR and both the rate of bone loss as measured by photonabsorptiometry (r = 0.7, p ¿ 0.001) and urinary hydroxyproline (r = 0.53, p < 0.001). The oestrogen-treated group had significantly lower values for WBR and rate of bone loss than the untreated group (p < 0.01, p < 0.01 respectively) indicating suppressed skeletal metabolism. However, the highest values were found in those who had defaulted from oestrogen therapy suggesting a rebound period of accelerated skeletal metabolism and bone loss. There was a significant negative correlation between WBR and oestrogen dosage (r = 0.75, p < 0.02) suggesting that it may be possible to adjust the dosage for optimal skeletal metabolic activity. WBR of diphosphonate provides a simple and sensitive measure of skeletal metabolism which correlates well with conventional measurements of bone loss. WBR may be useful in the screening and identification of women who have increased bone turnover just after the menopause and who may subsequently be at risk of osteoporosis developing.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106785     DOI: 10.1016/s0140-6736(80)92707-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  10 in total

Review 1.  Heterogeneity of osteoporotic syndromes and the response to calcitonin therapy.

Authors:  L V Avioli
Journal:  Calcif Tissue Int       Date:  1991       Impact factor: 4.333

2.  Nondestructive measurement of bone mineral in femurs from ovariectomized rats.

Authors:  D B Kimmel; T J Wronski
Journal:  Calcif Tissue Int       Date:  1990-02       Impact factor: 4.333

3.  Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion--a refined index of bone metabolism.

Authors:  L Hyldstrup; P McNair; P Ring; O Henriksen
Journal:  Eur J Nucl Med       Date:  1987

4.  99mTc-MDP retention in osteoporosis: relationship to other indices of bone cell activity and response to calcium and vitamin D therapy.

Authors:  M W Davie; J M Britton; M Haddaway; I W McCall
Journal:  Eur J Nucl Med       Date:  1987

5.  Treating the menopause.

Authors:  I D Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

6.  Accuracy of 24-h whole-body (skeletal) retention of diphosphonate measurements.

Authors:  I Fogelman; R Bessent; J E Scullion; G F Cuthbert
Journal:  Eur J Nucl Med       Date:  1982

7.  Whole body retention of 99mTc-diphosphonate. Relation to biochemical indices of bone turnover and to total body calcium.

Authors:  K Thomsen; J Johansen; L Nilas; C Christiansen
Journal:  Eur J Nucl Med       Date:  1987

8.  Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.

Authors:  R Civitelli; S Gonnelli; F Zacchei; S Bigazzi; A Vattimo; L V Avioli; C Gennari
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

9.  Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.

Authors:  O J Degrossi; M Ortiz; E B Degrossi; H García del Río; J C Barreira; D Messina; E Kerzberg; E J Roldán; E Montuori; A Pérez Lloret
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Minimum Standardized Uptake Value from Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Femoral Head Viability in Patients with Femoral Neck Fracture.

Authors:  Hyun Gee Ryoo; Won Woo Lee; Ji Young Kim; Eunjung Kong; Woo Hee Choi; Joon-Kee Yoon
Journal:  Nucl Med Mol Imaging       Date:  2019-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.